Search 

Pangaea Data Limited have pioneered a product based on their novel unsupervised AI to unlock hidden value from unstructured textual health data, which comprises 80% of patient records and >90% of medical blogs and social media feeds. Pangaea’s product is used by scientists from the Biopharmaceutical industry to extract intelligence such as phenotypes (clinical features) so they can stratify patients effectively and find more patients for drug discovery, clinical trial and new product launches at scale, which is otherwise challenging, especially in the context of hard to diagnose conditions such as rare and chronic diseases where 60% of the patient population is not diagnosed properly. The company has access to more than 500 million patient electronic health records through its partnerships with hospitals and other such providers from the US, UK, Europe, South America and Asia Pacific.

Biopharmaceutical companies are also using the product to automatically generate clinical study reports and the likes from experimental data and to find adverse events for Pharmacovigilance purposes. Pangaea continually publish their work in high impact peer reviewed journals.

Pangaea is based in San Francisco, London and Hong Kong and was founded by experienced entrepreneurs who have raised more than £130 million through their academic research and is advised by leading experts from industry, Imperial College London and Stanford University.

Precision is the first global precision medicine clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.

We focus on patients to reveal the complex personal biology of chronic diseases.

Our unique analytics are driving the next wave of precision medicine insights – finding new treatment opportunities for patients’ unmet medical needs in metabolic, inflammatory, respiratory, cardiovascular, women’s health, neurodegenerative and neuropsychiatric diseases.

Better understanding of complex disease biology -
We believe that deciphering the complex combinatorial influences on disease biology in patient sub-groups is at the heart of successful drug programs
High-resolution stratification of populations and people.

Accurately defining sub-groups of patients -
Enables us to understand their disease risks and drivers, select the right patients for trials, and the right treatment for a patient.

New disease insights through collaboration -
We bring together data partners, charities, healthcare and life science companies, and Key Opinion Leaders to advance chronic disease outcomes.

We work with multi-disciplinary groups and organizations in disease collaborations to advance the understanding and treatment of chronic disease. Bring your data and expertise and work with our team and industry partners.

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and  integrated antigen characterization platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. We are committed to helping you take your studies to success through product innovation, responsive service and focused application support, saving you time and money and reducing risk.